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Abstract
Background: Clinical evidence indicates the diabetes-induced 
impairment of osteogenesis caused by a decrease in osteoblast 
activity. Flavonoids can increase the differentiation and 
mineralization of osteoblasts in a high-glucose state. However, 
some flavonoids such as luteolin may have the potential to induce 
cytotoxicity in osteoblast-like cells. This study was performed 
to investigate whether a cytoprotective concentration range of 
luteolin could be separated from a cytotoxic concentration range 
in human MG-63 osteoblast-like cells in high-glucose condition.
Methods: Cells were cultured in a normal- or high-glucose 
medium. Cell viability was determined with the MTT assay. 
The formation of intracellular reactive oxygen species (ROS) 
was measured using probe 2’,7’ -dichlorofluorescein diacetate, 
and osteogenic differentiation was evaluated with an alkaline 
phosphatase bioassay.
Results: ROS generation, reduction in alkaline phosphatase 
activity, and cell death induced by high glucose were inhibited 
by lower concentrations of luteolin (EC50, 1.29±0.23 µM). 
Oxidative stress mediated by high glucose was also overcome 
by N-acetyl-L-cysteine. At high concentrations, luteolin caused 
osteoblast cell death in normal- and high-glucose states (IC50, 
34±2.33 and 27±2.42 µM, respectively), as represented by 
increased ROS and decreased alkaline phosphatase activity.
Conclusion: Our results indicated that the cytoprotective action 
of luteolin in glucotoxic condition was manifested in much 
lower concentrations, by a factor of approximately 26 and 20, 
than was its cytotoxic activity, which occurred under normal or 
glucotoxic condition, respectively.
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Introduction
Diabetes mellitus is a common metabolic disease that affects 
multiple organs and tissues, including bone.1 In vivo studies in 
diabetic rodent models indicate that impaired bone formation 
appears to be a major contributing factor to diabetes-mellitus-
related osteopenia.2 Although it is known that diabetes mellitus 
affects bone, the exact mechanism is not yet clear. One of the 
possible underlying processes, in addition to advanced glycation 
end products, has been linked to the inhibition of osteoblast 
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What’s Known
•	 Diabetes	 induces	 the	 impairment	
of osteogenesis through a decrease in 
osteoblast activity. 
•	 Flavonoids	 increase	 the	
differentiation and mineralization of 
osteoblasts in hyperglycemia.
•	 Luteolin	 has	 shown	 an	 anabolic	
property in mouse osteoblastic 
MC3T3-E1	 cells.	 Most	 flavonoids,	
including luteolin, also demonstrate 
dose-dependent cytotoxicity.
What’s New
•	 In	the	present	study,	luteolin	showed	
modulatory effects on the osteogenic 
characteristics of human osteoblast-
like MG-63 cells under normal and high 
glucose conditions in vitro.
•	 Low	 concentrations	 of	 luteolin	
had a protective action against 
hyperglycemic insult in MG-63 cells. 
High concentrations of luteolin 
demonstrated cytotoxicity in both 
normal and high glucose states.
•	 Cytoprotective	 levels	 of	 luteolin	
were lower, by a factor of approximately 
20-26, than its cytotoxic concentrations.
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function and the reduced formation of a 
mineralized matrix.3 One of the major molecular 
changes in diabetes mellitus is the formation 
of reactive oxygen species (ROS) as a result 
of high glucose and/or insulin insufficiency 
or resistance.4 In osteoblasts, ROS has been 
reported to inhibit differentiation as evidenced 
by core-binding factor α 1 (Cbfal)/runt-related 
transcription factor 2 (RUNX2), which is a key 
transcription factor associated with osteoblast 
differentiation. The differentiation markers, 
including alkaline phosphatase (ALP) and type I 
collagen, decrease in the presence of oxidative 
stress.5 In one study on subjects with type 1 
diabetes, serum ALP and osteocalcin levels 
were significantly lower than those of the control 
subjects, suggesting reduced bone formation.6
Flavonoids	 are	 known	 to	 have	 multiple	
beneficial biological effects owing to their anti-
inflammatory,7 antioxidant,8 and antidiabetic9 
activities. Available literature suggests that 
flavone apigenin, identified as the main 
flavonoid in soybean, may prevent bone loss in 
ovariectomized animal models and that it may 
inhibit osteoclast differentiation.10 However, 
quercetin, one of the main dietary flavonoids 
happening in foods of plant origin, is reported 
to induce apoptosis in osteoblastic cells.11 
Luteolin, a flavone rich in many plants, has anti-
inflammatory effects both in vivo and in vitro.12 
Moreover, luteolin has an anabolic property in that 
not only does it raise the synthesis of collagen, 
activity of ALP, and secretion of osteocalcin 
but also it hinders 3-morpholinosydnonimine-
triggered generation of pro-inflammatory 
mediators in osteoblastic MC3T3-E1 cells 
in vitro.13 Nonetheless, it has been reported 
that luteolin markedly diminishes the viability of 
osteoblastic MC3T3-E1 cells, demonstrating the 
cytotoxic activity of this flavoniod.14
Thus, we designed the present study to 
collect data on the concentration-response 
relation between the protective and cytotoxic 
effects of luteolin on human MG-63 osteoblast-
like cells under high-glucose versus normal-
glucose states to distinguish between luteolin 
cytoprotective and cytotoxic concentration 
ranges.
Materials and Methods
Cell Culture
Human osteoblast-like MG-63 cell line was 
obtained from the National Cell Bank of Iran 
(NCBI) (c-555) at Pasteur Institute. The cells were 
cultured in Dulbecco’s modified Eagle medium 
(DMEM) (Gibco), supplemented with 10% 
fetal	 bovine	 serum	 (FBS)	 (Gibco),	 100	IU/mL	
of penicillin, and 100 mg/mL of streptomycin 
at 37°C in 95% humidified air with 5% CO2. 
The medium was replaced every 3 days, and 
the confluent cells were digested with 0.25% 
trypsin. The cells between the second and fifth 
passages were used in the following studies. 
Cell viability was assessed via the trypan blue 
exclusion method. The MG-63 cells were 
divided into 6 groups: control group (original 
DMEM medium), normal-glucose group (5.5 mM 
of glucose), high-mannitol group (30 mM of 
mannitol as osmotic control), high-glucose group 
(30 mM of glucose),15 and 2 luteolin (Sigma) 
treatment groups in normal- and high-glucose 
states. The concentrations of luteolin used for 
the cell viability test were 0.05, 0.1, 0.25, 0.5, 
1, 5, 10, 25, 50, and 100 µM. The experiments 
were conducted in media with either normal 
or high glucose or high mannitol for 24, 48, 
and 72 hours. The time point of 48 hours was 
selected for the treatment exposure.
Cell Viability Assay
The cytotoxic effects of luteolin on the 
human MG-63 osteoblast-like cells were 
evaluated via the 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT)-based 
experiment.16 The MG-63 cells were plated at 
a density of 3×104 cells/well in 96-well plates. 
After overnight incubation in a humidified 
incubator with 5% CO2 at 37°C, the cultures 
were continued for 48 hours in the medium. 
The MTT (20 μL, 5 mg/mL) was then added to 
each well, and the cultures were continued for 
4 hours at 37°C. The medium was subsequently 
aspirated, and 150 µL of dimethyl sulfoxide 
was added to each well. The supernatant was 
transferred to microplate wells, and colorimetric 
changes were quantified in a microplate reader 
(Dynex MRX) at a wavelength of 570 nm. The 
MTT colorimetric assay was performed in 
triplicate. The percentage of cell viability was 
calculated using the following formula: %cell 
viability=[(Mean Abs. of the samples-Mean Abs. 
of the blank)/(Mean Abs. of the control-Mean 
Abs. of the blank)]×100.
The half maximal effective concentration 
(EC50) and the half maximal inhibitory 
concentration (IC50) were calculated in 
normal- and high-glucose conditions.
Measurement of Reactive Oxygen Species 
Formation
For	the	measurement	of	ROS,	all	the	cells	were	
incubated with 10 µM of 2’, 7’-dichlorfluorescein 
diacetate	(DCFH2-DA) (Sigma)17 in a serum-free 
culture medium for 45 minutes at 37°C and 5% 
CO2. During oxidative stress, the added chemical 
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compound	 (i.e.,	DCFH2-DA) was catalyzed to 
2`7`-dichlorofluorescein	 (DCFH)	 and	 analyzed	
in a bioassay multi-detection fluorescent plate 
reader	 (Biotek-FLx800)	 at	 excitation/emissions	
of 485/520 nm. The production of ROS was 
determined from an H2O2 standard curve (10 to 
200 nM).
Assay of Alkaline Phosphatase Activity
The human MG-63 osteoblast-like cells 
were seeded in a 96-well plate, with 3,000 cells 
per well, and placed in 5% CO2 at 37°C for 
48 hours.18 After being rinsed with phosphate-
buffered saline, the cells were treated with 
various concentrations (i.e., 1, 5, 50, and 
100 µM) of luteolin. After the removal of the 
medium, the cells of each well were fixed with 
100 µL of 4% formaldehyde for 10 minutes. 
After washing, the cells of each well were 
treated with 30 µL of p-nitrophenyl phosphate 
(pNPP) at 37°C for 30 minutes to determine 
ALP activity. Afterward, 30 µL of 0.5 N NaOH 
was added to terminate the reaction. Lastly, 
pNPP was converted to p-nitrophenol utilizing 
an ELISA reader at a wavelength of 405 nm, 
and the relative level of ALP activity over control 
was measured. Moreover, a protein synthesis 
inhibitor (i.e. cycloheximide [1 µM]), was studied 
in the MG-63 osteoblast-like cells.
Statistical Analysis
The results are expressed as mean±SEM. The 
statistical evaluation of the data was performed 
with the Student t-test for simple comparison 
between	2	values	when	appropriate.	For	multiple	
comparisons, the data were analyzed using the 
analysis of variance. A P<0.05 was considered 
statistically significant. The terms “EC50” and 
“IC50” are the statistically derived concentrations 
of a substance in an environmental medium 
expected to produce a certain effect in 50% of 
the test organisms in a given population under 
a defined set of conditions after a specified 
exposure time.
Results
Effects of High Glucose on Cell Viability
The human MG-63 osteoblast-like cells were 
exposed to 30 mM of either glucose or mannitol. 
On day 1, the MTT assay indicated no significant 
differences in cell viability between the high- and 
normal-glucose groups. On days 2 and 3, 
the MG-63 cells in the high-glucose medium, 
compared to the normal-glucose medium, 
showed significantly decreased optical density 
(data not shown) (P=0.006). Mannitol, which 
was used to create a high-osmotic pressure 
mimicking high-glucose condition, did not show 
significant changes in cell viability. The time 
point of 48 hours was selected as the treatment 
exposure time.
Effect of Luteolin on Cell Viability
Luteolin at very low concentrations (i.e. 0.05 
and 0.1 µM) did not change high-glucose-induced 
cell death in the human MG-63 osteoblast-like 
cells; while at low concentrations (i.e., 0.25, 0.5, 
1, and 5 µM), it attenuated high-glucose-induced 
cell death (P=0.009, P=0.008, P=0.008, and 
P=0.005, respectively, vs. high-glucose control) 
with an EC50 value of 1.29±0.23 µM. Additionally, 
10 µM of luteolin decreased cell viability 
compared to the previous dilution (i.e., 5 µM) in 
both normal- and high-glucose states (P=0.031). 
However, 10 µM of luteolin was still able to 
partially suppress high-glucose-induced cell 
death (P=0.007 vs. high-glucose control). In 
our experiments, the MG-63 cells underwent 
severe cell death after high concentrations of 
luteolin (i.e., 25, 50, and 100 µM) treatment 
for 48 hours with IC50 values of 34±2.33 and 
27±2.42 µM in normal- and high-glucose states, 
correspondingly (Figure 1). A near-significant 
difference (P=0.052) was found between the IC50 
values obtained in normal- and high-glucose 
conditions. The reduction in cell viability by the 
high concentrations of luteolin was greater than 
that observed by high-glucose control (P=0.039, 
P=0.009, and P=0.006, respectively). The 
molecular-level experiments were limited to 1 and 
5 µM as low- and 50 and 100 µM as high-luteolin 
concentrations, which showed cytoprotective 
and cytotoxic activities, respectively.
Effect of Luteolin on the Generation of Reactive 
Oxygen Species
The effect of luteolin on the generation of 
ROS in the human MG-63 osteoblast-like cells 
is shown in Figure 2. We used the fluorescent 
Figure 1: Effect of different concentrations of luteolin on 
osteoblast-likeMG-63 cell viability. The MG-63 cells were 
treated with normal glucose (NG), high glucose (HG), high 
mannitol (HM), NG plus luteolin, and HG plus luteolin at 37°C 
in 5% CO2. Data are expressed as mean±SEM. * P<0.05 vs. 
NG and HM.  **P<0.01 vs. NG, #P<0.05 vs. HG, ##P<0.01 
vs. HG.
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probe	DCFH2-DA to assess the release of ROS 
in the MG-63 cells and found that the incubation 
of these cells in high glucose for 48 hours 
markedly increased the fluorescence intensity 
of	DCF	(P=0.006	vs.	normal	glucose),	indicating	
significant ROS-induced stress in the model. 
Treatment with low concentrations of luteolin 
and N-acetyl-L-cysteine (5 mM)19 prevented the 
enhancement	 of	 DCF	 fluorescence	 intensity.	
However, high concentrations of luteolin 
increased ROS generation in both normal- and 
high-glucose states in the MG-63 cells. High-
concentration mannitol had no effects on the 
level of ROS.
Effect of Luteolin on Alkaline Phosphatase 
Activity
ALP activity was significantly reduced in the 
high-glucose-cultured MG-63 cells. Treatment 
with low concentrations of luteolin restored ALP 
activity in the cells exposed to high glucose. 
Nonetheless, the effect of luteolin (5 µM) 
in increasing ALP activity was completely 
eliminated in the presence of cycloheximide 
(1 µM)13 (P=0.008 vs. normal glucose). 
Furthermore,	 ALP	 activity	 was	 reduced	 after	
treatment with high concentrations of luteolin 
in both of the normal- and high-glucose-treated 
human MG-63 osteoblast-like cells (Figure 3).
Discussion
We used human MG-63 osteosarcoma cells to 
investigate the modulatory effects of luteolin on 
osteogenic characteristics under normal- and 
high-glucose conditions. These cells display 
osteoblast-like properties with rapid cell growth 
and no interspecies differences.20 ALP activity 
and osteocalcin are examples of the phenotypic 
markers that MG-63cells can exhibit.21 In the 
present study, the exposure of human MG-63 
osteoblast-like cells to high glucose for 48 and 
72 hours resulted in a significant decrease in 
cell viability, as compared with cells cultured in a 
normal-glucose or a high-mannitol concentration. 
Previously reported in vitro studies have 
indicated that oxidative stress inhibits osteoblast 
differentiation5 and induces osteoblastic insults 
and apoptosis.22 An imbalance between bone-
forming osteoblasts and bone-resorbing 
osteoclasts leads to the pathogenesis and 
etiology of certain bone metabolic diseases, 
including osteoporosis and osteopetrosis.23 
It is presumed that diabetes-induced adverse 
sequelae are largely due to oxidative stress, 
which leads to the augmentation of ROS 
production under hyperglycemic state, capable 
of inducing disturbances in cellular functioning 
in various cell types. Oxidative stress is induced 
by a variety of mechanisms, including formation 
of increased advanced glycation end products, 
increased polyol pathway flux, activation of 
protein kinase C isoforms, glucose autoxidation, 
and mitochondrial overproduction of superoxide 
under diabetic conditions.4
In the present study, treatment with luteolin 
at low concentrations (i.e., 0.25, 0.5, 1, and 
5 µM) prevented high-glucose-mediated cell 
death with an EC50 value of 1.29±0.23 µM 
and at high concentrations (i.e., 25, 50, and 
100 µM) reduced cell viability with an IC50 
value of 27±2.42 µM. Both cytoprotective and 
cytotoxic effects of luteolin were exhibited in 
a concentration-dependent manner. Under 
normal-glucose condition, low concentrations 
of luteolin had no effects on cell viability in the 
MG-63 cells. Nevertheless, treatment with high 
concentrations reduced cell viability with an IC50 
value of 34±2.33 µM. A comparison of the toxicity 
of luteolin between the normal- and high-glucose 
groups revealed a near-significant difference 
(P=0.052) between the IC50 values obtained 
Figure 2: Effect of different concentrations of luteolin on 
the generation of reactive oxygen species (ROS) in normal- 
(NG) and high-glucose (HG) states. Bar graphs show ROS 
production (%) in MG-63 osteoblast-like cells exposed to 
NG, high mannitol (HM), HG, HG plus N-acetyl-L-cysteine 
(NAC) (5 mM), NG plus luteolin, and HG plus luteolin. Data 
are expressed as mean±SEM. *P<0.05 vs. NG and HM, 
**P<0.01 vs. NG and HM, ##P<0.01 vs. HG. 
Figure 3: Effect of different concentrations of luteolin (Lu) 
on alkaline phosphatase (ALP) activity in normal- (NG) and 
high-glucose (HG) states. Bar graphs show ALP activity (%) 
in MG-63 osteoblast-like cells exposed to NG, high mannitol 
(HM), HG, HG plus cycloheximide (Cy) (1 µM), Lu (5 µM) plus 
Cy (1 µM), NG plus Lu, and HG plus Lu. Data are expressed 
as mean±SEM. * P<0.05 vs. NG and HM. **P<0.01 vs. NG 
and HM, ##P<0.01 vs. HG. 
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in normal- and high-glucose conditions. We 
suggest that future studies investigate whether 
hyperglycemia can potentiate the toxicity of 
luteolin in human osteoblastic cells.
Studies on osteoblasts have shown that 
the total flavonoids from Herba Epimedii 
have osteoblastic proliferation-stimulating 
activity toward osteoblast-like UMR106 cells.24 
Moreover, myricetin, a naturally occurring 
flavonoid, was reported to protect osteoblasts 
from 2-deoxy-D-ribose-induced dysfunction and 
oxidative damage in MC3T3-E1 cells, mouse 
pre-osteoblast cell line.25 It was also reported 
that luteolin, under normal-glucose condition, 
inhibited osteoclast bone resorption with an 
EC50 value of approximately 2.5 µM.26 However, 
consistent with our results, a study demonstrated 
that 25 and 50 µM of luteolin significantly reduced 
the number of viable MC3T3-E1 cells compared 
with untreated cells.14 Furthermore,	 quercetin	
may exert both protective and deleterious 
effects in bone repair.11 In a study, quercetin 
inhibited osteoblast proliferation, differentiation, 
and mineralization.27 Quercetin also induced 
apoptosis through a mitochondria-dependent 
mechanism.11 Concentration-dependent 
cytoprotective and cytotoxic activity of luteolin 
has been previously demonstrated in human 
umbilical vein endothelial cells.28
We demonstrated that luteolin at low 
concentrations, as well as N-acetyl-L-cysteine, 
decreased intracellular ROS in high-glucose 
condition. Nonetheless, treatment with high 
concentrations of luteolin resulted in augmented 
intracellular ROS in both normal- and high-
glucose states in a concentration-dependent 
manner. Different flavonoids have been shown 
to augment antioxidant enzyme activities 
in osteoblastic cells. The results of a study 
demonstrated that quercetin diminished 
oxidative damage in human osteoblastic 
cell by scavenging radicals.29 An extract of 
total flavonoids from persimmon leaves was 
shown to significantly decrease the level 
of ROS in MC3T3-E1 cells.30 Moreover, an 
investigation reported that the total flavonoids in 
Chrysanthemum zawadskii decreased 2-deoxy-
D-ribose-induced cell damage in MC3T3-E1 
osteoblastic cells due to its antioxidant activity 
and positive effect on differentiation and 
suggested that it might promote bone recovery 
in diabetes-associated bone diseases.21 Another 
study demonstrated that glabridin, a flavonoid, 
attenuated 2-deoxy-D-ribose-induced cell 
damage in osteoblastic cells and suggested that 
it might be useful for the treatment of diabetes-
related bone disease.31 Elsewhere, a study 
showed that morin, a member of flavonols, 
alleviated diabetic-induced osteopenia and 
postulated that this effect was through its both 
anti-inflammatory and antioxidant properties.32
ALP has been generally considered a 
well-known early marker of differentiation 
in osteoblasts.33 A study found that high 
concentrations of glucose inhibited ALP 
activity, collagen formation, and mineralization 
in osteoblastic cells.6 In the present study, the 
activity of ALP was utilized as an osteoblast 
differentiation and maturation indicator. Our 
results showed that luteolin at low concentrations 
increased ALP activity in human MG-63 
osteoblast-like cells, indicating its anabolic 
effect. The enhancing effect of luteolin at 5 µM 
on ALP activity in MG-63 cells was blocked 
completely by the presence of cycloheximide, an 
inhibitor of protein synthesis. Thus, the anabolic 
effect of luteolin may be based partly on a newly 
synthesized protein component. However, we 
demonstrated that luteolin at high concentrations 
decreased ALP activity in both normal- and high-
glucose states in a concentration-dependent 
manner. A previous investigation reported that 
a low concentration of luteolin (1 µM) increased 
ALP activity in osteoblastic MC3T3-E1 cells 
in vitro.13 Another study demonstrated that 
hesperetin, which is classified in flavanone 
subgroup and is largely specific to citrus fruits, 
ameliorated the suppression of osteogenesis 
caused by high glucose in stem cells obtained 
from periodontal ligaments (as assessed via 
the measurement of ALP activity).34 The results 
of another research indicated that a high 
concentration of luteolin (16 µM) decreased ALP 
activity in MC3T3-E1 cells.14
Based on our findings, careful attention 
should be paid to the amount of luteolin in foods 
or supplements available for consumption. 
Flavonoid	 supplements	 are	 aggressively	
marketed by the nutraceutical industry for 
various purposes.35 In addition, luteolin, as a 
common dietary flavonoid, is found in many 
medicinal herbs, fruits, and vegetables such 
as green pepper, chamomile tea, perilla leaf,36 
parsley, and artichoke.37 Also, high amounts of 
luteolin can be found in peanut hulls.37
We demonstrated the cytoprotective and 
cytotoxic activity of low and high concentrations, 
respectively, of luteolin in osteoblast-like cells in 
normal- and high-glucose states; nonetheless, 
there	 are	 some	 limitations	 in	 our	 study.	 First	
and foremost among these limitations is that 
we considered only 1 time point (i.e., 48 h) as 
the treatment exposure in the experiments. 
Although this time point was the optimal duration 
of incubation in our previous studies, using 
longer exposure times in the case of osteoblastic 
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cells may provide more precise results. Another 
shortcoming of note is that we determined the 
activity of only 1 osteoblast differentiation marker 
(i.e., ALP), although there are some other 
osteoblast markers whose assessment would 
be helpful. Currently, the present study is being 
continued in our laboratory and some experiments 
are underway to provide supplementary data.
Conclusion
Taken together, our results showed that low 
concentrations of luteolin had a protective effect 
against hyperglycemic stress in human MG-63 
osteoblast-like cells by reducing intracellular 
ROS overproduction, thereby restoring ALP 
activity. In contrast, high concentrations totally 
reversed the above-mentioned effects. Luteolin at 
much lower concentrations conferred protection 
against high-glucose-induced cell death, by a 
factor of approximately 26 and 20, compared 
to its cytotoxic activity under both normal- and 
high-glucose conditions, respectively. Thus, it 
is safest to avoid taking high doses of luteolin 
in food supplements when its protective actions 
are desired.
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